RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21
|Posted date||Oct 28, 2019|
|International application number||2019JP009867|
|International publication number||WO 2019176901|
|Date of international filing||Mar 12, 2019|
|Date of international publication||Sep 19, 2019|
|Title||RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21|
|Abstract||An objective of the present invention is to elucidate the cause of pain in osteoarthritis and to contribute to the development of a therapeutic agent for alleviating the pain of osteoarthritis. An agent for relieving pain from osteoarthritis, the agent including an MiR-21 inhibitor as the active ingredient, or an agent for relieving pain from osteoarthritis, the agent including a TLR antagonist as the active ingredient.|
|Outline of related art and contending technology||
Osteoarthritis (osteoarthritis: OA) is a high prevalence, and has the chronic disease. Heisei 25th Life of the population based care insurance perspective view of the support according to the investigation of care is required at 1 the main cause of the pain of a joint, the joint of the subjective symptom of the population in the upper limb and the pain. Osteoarthritis drug therapies for pain alleviation of non-steroidal anti-inflammatory drug or acetaminophen, opioid or the like is used, the effectiveness is insufficient due to the artificial joint replacement in the case where a therapy such as surgery on the increase. Of an existing drug therapy may have many adverse effects of acute, chronic for deleterious effect associated with the use, the development of new analgesic has been desired. In the cause of the pain of osteoarthritis is still not clear, for the development of new analgesic osteoarthritis in the cause of the pain is required.
In recent years, a variety of diseases in pain associated with the importance of the microRNA has been reported that, in the pain of osteoarthritis of the little report microRNA function.
In a recent study, extracellular microRNA Toll-like receptor cell in the 7 after binding (Toll like receptor; TLR), a variety of physiological functions have been reported. TLR7 Is, the sensation of pain associated with the function of the spinal cord dorsal root ganglia (DRG) smaller neuronal (sensory) and expressed, and pain involved in the control are known.
Patent Document 1 is (US 9267139 B2), as an example of a musculo-skeletal diseases illustrated in osteoarthritis, as a treatment method, attention is paid to the miRNA, or reduces the expression of miR-29b-1 discloses a method for controlling. However, 29 years-41 years of age from the patient's bone marrow mesenchymal stem cells (BMSCs) 64 of the age of-73 years as compared to the change in microRNA BMSCs remains being examined, and possibly also adaptive disease is likely to be as long as the relationship between the disease and is not intended to be written, an agent involved in the expression of microRNA (microRNA inhibitors and the like) not to mention whether or not to control pain, an agent involved in the expression of microRNA expression of the microRNA to the actual change is not to confirm. Further, the fact that the treatment of osteoarthritis, or whether the treatment of pain treatment of cartilage degeneration is not expressly recited.
Patent Document 2 (WO 2013/151058) is, by controlling the expression of the miR-140, osteoarthritis or degenerative disc disease of the cartilage such as the method for treating a disease is disclosed, this is, the pain of osteoarthritis therapeutic agent but, by controlling the differentiation of cartilage, in the treatment of osteoarthritis. Cartilage degeneration does not correlate with the number of reports that the pain is present, although the present invention are different.
Patent Document 3 (JP Patent Application 2012-504651) is, by inhibiting the activity of TLR3, and a method for treating inflammatory conditions, one aspect of the osteoarthritis are listed, only, but only listed.
Patent Document 4 (JP Patent Application 2011-502170) is, the disease treatment or prevention of osteoarthritis TLR4 antagonist for use. TLR4 Is activated, due to an increase in the release of inflammatory cytokines, osteoarthritis inflammatory response by the onset of the disease that is linked to the present invention, TLR7, 8, 9 is not of interest.
Patent Document 5 (JP Patent Application 2016-512561) is, in order to reduce the pain and TLR4 antagonist is noted that the present invention. As a disease, and osteoarthritis However, TLR7, 8, 9 is not of interest. In addition, lower back pain, pain in the vulva, trigeminal neuralgia, such as migraine test is performed for, for osteoarthritis, no test is not performed.
TLR antagonists it is needless to say, the type of receptor is different from that of the site of action, in a completely different.
|Scope of claims||
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21 "
- NIPPON MEDICAL SCHOOL INTEPP CENTER
- URL: https://www.nms.ac.jp/tlo/
- Address: (In Japanese)〒113-8602 東京都文京区千駄木１－１－５
- Fax: 03-3822-2834